Karen Costenbader, MD, discusses how early intervention with belimumab in patients with lupus significantly reduces disease flares and prevents irreversible organ damage.
Treatment with belimumab resulted in fewer flares in patients with either early or established systemic lupus erythematosus, especially among those with no baseline organ damage, according to data presented at the EULAR 2024 Congress.
“The benefits of early treatment of SLE for the prevention of repeated flares of disease activity, as well as the need to limit glucocorticoid exposure, are